TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Peijia Medical Ltd. ( (HK:9996) ) has provided an update.
Peijia Medical Ltd. announced that the National Medical Products Administration of China has accepted the registration application for its TaurusNXT® Non-glutaraldehyde Crosslinked Dry-tissue Transcatheter Aortic Valve Replacement system. This third-generation system features advanced technology aimed at reducing valve calcification and improving procedural safety, which may strengthen Peijia Medical’s position in the innovative medical devices sector.
The most recent analyst rating on (HK:9996) stock is a Sell with a HK$5.00 price target. To see the full list of analyst forecasts on Peijia Medical Ltd. stock, see the HK:9996 Stock Forecast page.
More about Peijia Medical Ltd.
Peijia Medical Ltd. is a company in the medical device industry, focusing on the development of innovative transcatheter valve products. Their primary products include transcatheter aortic valve replacement systems, with a market focus on enhancing the durability and biocompatibility of prosthetic aortic valves.
YTD Price Performance: 39.20%
Average Trading Volume: 1,511,737
Technical Sentiment Signal: Sell
Current Market Cap: HK$3.71B
See more insights into 9996 stock on TipRanks’ Stock Analysis page.